Overview of plans/perspectives/challenges of invited pharmaceutical companies on clinical trials in ALD/AH
EASL LiverTree™, Luciano Adorini, 198294
Overview of plans/perspectives/challenges of invited pharmaceutical companies on clinical trials in ALD/AH
EASL LiverTree™, Rob Ashley, 198086
Industry perspectives: Chair
EASL LiverTree™, Gyongyi Szabo, 198084
Overview of plans/perspectives/challenges of invited pharmaceutical companies on clinical trials in ALD/AH
EASL LiverTree™, Patrick Colin, 198085
PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3(PNPLA3) gene polymorphism in Alcoholic Liver disease in India.
EASL LiverTree™, Vaibhav Somani, 193401
Healthy donor fecal microbiota transplantation for severe alcoholic hepatitis related acute on chronic liver failure - Short term outcomes from a tertiary center in South India
EASL LiverTree™, Cyriac Philips, 193402
'You gotta want it': Misconceptions, preferences, and barriers to alcohol use treatment in alcoholic liver disease
EASL LiverTree™, Jessica Mellinger, 196326
Early Liver Transplantation for Acute Alcoholic Hepatitis: Pilot Program in a single Transplant Centre
EASL LiverTree™, Giacomo Germani, 196327
Persistence of decompensation despite abstinence in alcoholic cirrhosis is associated with poor outcomes and lower survival
EASL LiverTree™, Ana Clemente, 196328
Discussion
EASL LiverTree™, Session Speakers, 200935
Which therapeutic targets will be the most attractive in the future?
EASL LiverTree™, Craig McClain, 198083
How can large epidemiologic studies, registries and bio-banks may help in the setting of AH and ALD
EASL LiverTree™, Aleksander Krag, 198081
Clinical trial design: What is the optimal plan of development from phase I to Phase III?
EASL LiverTree™, Alexandre Louvet, 198080
Current treatments in alcoholic hepatitis (lessons learned) and ongoing clinical trials
EASL LiverTree™, Mark R. Thursz, 198079
Patient characteristics and end-points in clinical trials for early ALD
EASL LiverTree™, Helena Cortez-Pinto, 198078
Risk factors for alcohol relapse after liver transplantation: a 9-year retrospective study
EASL LiverTree™, Nekisa Zakeri, 193396
IgA antibodies against filamentous-actin are frequently detected in patients with cirrhosis and indicate a progressive disease course
EASL LiverTree™, Tamas Tornai, 193397
DETERMINANT OF DECOMPENSATION AND DEATH IN PATIENTS WITH ALCOHOLIC LIVER DISEASE AND LONGITUDINAL FOLLOW-UP
EASL LiverTree™, Marta Guerrero-Misas, 193398
Innate T cells are significantly altered in the livers of patients with alcoholic liver disease
EASL LiverTree™, Yasmeen Ghnewa, 193399
Liver-brain axis in alcoholic liver disease: Chronic alcohol induces recruitment of peripheral macrophages with different inflammatory gene expression profile into the liver and brain
EASL LiverTree™, Patrick Lowe, 193400
Bile acids and intestinal dysbiosis in alcoholic hepatitis
EASL LiverTree™, Dragos Ciocan, 193393
The STOPAH trial has altered clinical practice: results of a UK national survey
EASL LiverTree™, Ashwin Dhanda, 193394
Carriage of rs738409 in PNPLA3 is positively associated with the severity of histological damage in patients with alcoholic hepatitis
EASL LiverTree™, Stephen Atkinson, 193395
The rising healthcare burden of alcoholic cirrhosis in the United States
EASL LiverTree™, Jessica Mellinger, 196324
Characterization of alcoholic hepatitis using proteomics of PBMCs
EASL LiverTree™, Jon Jacobs, 196325
Discussion
EASL LiverTree™, Session Speakers, 198076
EMA process to validate end-points for drug approval: specific requirements for AH
EASL LiverTree™, Joachim Musaus, 198075
Regulatory process to validate biomarkers and end-points for drug approval: specific requirements for AH
EASL LiverTree™, Ruby MEHTA, 198074
Cost and mortality attributed to Alcoholic Liver Disease
EASL LiverTree™, Jürgen Rehm, 198073
Accurately defining infection as a clinical trial endpoint in patients with alcohol induced chronic liver disease: results from a multicentre feasibility study
EASL LiverTree™, Louise China, 193391
A STUDY OF PREDICTORS OF 90-DAY MORTALITY IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS: EXPERIENCE OUTSIDE CLINICAL TRIALS WITH 183 PATIENTS AT A TERTIARY CARE CENTER FROM INDIA
EASL LiverTree™, Ravi DASWANI, 193392
Impact of the Systemic Inflammatory Response and hyperdynamic circulatory syndromes on 91-Day Mortality Rates in Subjects with Severe Alcoholic Hepatitis Treated with the ELAD® System
EASL LiverTree™, William Frank, 196322
SALVE data base and inventory: a multinational effort to increase case numbers in cohorts of people with ALD
EASL LiverTree™, Carolin Lackner, 196323
Discussion
EASL LiverTree™, Session Speakers, 198071
Alcohol relapse after transplantation: does it matter?
EASL LiverTree™, Georges-Philippe PAGEAUX, 198070
Post-transplant complications/what is specific for ALD
EASL LiverTree™, Patrizia Burra, 198069
Early liver transplantation in AH - Pro and Con debate: I favour broader use of early liver transplantation in AH
EASL LiverTree™, Philippe MATHURIN, 198068
Early liver transplantation in AH - Pro and Con debate: I do not favour broader use of early liver transplantation for AH
EASL LiverTree™, Michael Lucey, 198067
SIRS and management of infection in AH
EASL LiverTree™, Ramon Bataller, 198066
Acute AH: Defining disease severity (severe vs. moderate AH) and prognostic models of lethality and survival
EASL LiverTree™, Patrick Kamath, 198065
EXTRACELLULAR VESICLES FROM SUBJECTS WITH ALCOHOLIC LIVER DISEASE ARE INCREASED IN NUMBER, ENRICHED IN SPHINGOLIPIDS AND CORRELATED WITH THE SEVERITY OF THE DISEASE
EASL LiverTree™, Juan Pablo Arab, 193389
Three treatment options in severe alcoholic hepatitis
EASL LiverTree™, Petr Tkachenko, 193390
Both MELD Score and Number of Organ Failures Defined by the Latest Chronic Liver Failure-Organ Failure Scoring System Effectively Select Subjects with Severe Alcoholic Hepatitis with Good Outcomes when Treated with the ELAD® System
EASL LiverTree™, Robert Ashley, 196319
Lactobacillus rhamnosus GG supplementation decreases liver steatosis in a zebrafish model of alcoholic liver disease
EASL LiverTree™, Juliana Bruch, 196320
PREDICTORS OF 90-DAY MORTALITY IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS: EXPERIENCE OUTSIDE CLINICAL TRIALS WITH 183 PATIENTS AT A TERTIARY CARE CENTER FROM INDIA
EASL LiverTree™, Ravi DASWANI, 196321
Bayesian sparse regression modelling more accurately predicts mortality risk than commonly used prognostic scoring systems in patients with severe alcoholic hepatitis
EASL LiverTree™, Stephen Atkinson, 193386
Extracellular pro-inflammatory ASC specks released by inflammasome-mediated pyroptosis to the circulation in alcoholic hepatitis and deposition of bioactive ASC oligomers in human and murine livers are biomarkers and mediators of alcoholic hepatitis
EASL LiverTree™, Arvin Iracheta-Vellve, 193387
Alcohol binge induces spontaneous release of neutrophil extracellular traps; however, it impairs stimulation-induced NET formation and macrophage efferocytosis in alcohol associated severe sepsis in mice
EASL LiverTree™, Yeonhee Cho, 193388
Transcriptomics of liver tissue, PBMCs, and monocytes in alcoholic hepatitis
EASL LiverTree™, Trina Norden-Krichmar, 196317
Transcription factor complex TRIM33-Smad2/3 is crucial for progenitor cell-mediated liver regeneration in alcoholic hepatitis
EASL LiverTree™, Steven Dooley, 196318
State-of-the-Art Lecture: Molecular pathways in hepatocellular carcinoma
EASL LiverTree™, Michael Karin, 198063
Discussion
EASL LiverTree™, Session Speakers, 198062
Non-invasive assessment including imaging in early versus advanced ALD
EASL LiverTree™, Laurent Castera, 198061
Liquid Biopsy and Biomarkers is a Diagnostic Measure in Surrogate End-Point in Alcoholic Hepatitis
EASL LiverTree™, Vijay Shah, 198060
Liver histology and AH/ALD - what is its role?
EASL LiverTree™, Dina Tiniakos, 198059
Alcohol use disorder: diagnosis and management
EASL LiverTree™, Giovanni Addolorato, 198057
Autonomic function is impaired across the spectrum of NAFLD and alcohol drinkers
EASL LiverTree™, David Houghton, 193384
Functional polymorphisms of innate immunity pattern recognition receptors do not constitute the risk of bacterial infections other than spontaneous bacterial peritonitis and also not the progressive disease course in patients with cirrhosis
EASL LiverTree™, Tamas Tornai, 193385
AlcoChange, A Pilot Study of a Smartphone Tool to Reduce Alcohol Consumption in Alcohol-Related Liver Disease - An Interim Analysis.
EASL LiverTree™, Aida Nadar, 196315
Gene expression of miR-122, miR-217 and miR 155 in alcoholic liver disease in zebrafish
EASL LiverTree™, Mario Alvares-da-Silva, 196316
Animal models of ALD and alcoholic hepatitis:Intragastric alcohol feeding model for identifying key therapeutic pathways
EASL LiverTree™, Hidekazu Tsukamoto, 198054
Animal models of ALD and alcoholic hepatitis: I favour the NIAAA model for targeting the key therapeutic pathways
EASL LiverTree™, Bin Gao, 198053
Impaired pathways of liver regeneration in chronic liver disease: future therapeutic target for severe ALD?
EASL LiverTree™, Anna Mae Diehl, 198052
Inflammation as a driver of ALD
EASL LiverTree™, Gyongyi Szabo, 198050
Liver.pt: a picture of alcoholic liver disease ambulatory patients through a national multicentric registry
EASL LiverTree™, Elisa Gravito-Soares, 193380
T cell cytokine profile predicts 90-day outcome in patients with severe alcoholic hepatitis
EASL LiverTree™, Ashwin Dhanda, 193381
Outcomes and recidivism in patients undergoing living donor liver transplantation for severe alcoholic hepatitis
EASL LiverTree™, Mihir Vora, 193382
Abstinence period before liver transplantation: a meta-analysis of the 6 months rule
EASL LiverTree™, Moritz Tobiasch, 193383
Peripheral blood CD4+ T helper cells (Th1, Th2, Th17, Th22) are increased in severe alcoholic hepatitis
EASL LiverTree™, Zhang-Xu Liu, 196314
Opportunities to reach high-risk populations for alcoholic liver cirrhosis: Systematic review and meta-analysis
EASL LiverTree™, Gro Askgaard, 193377
Effect of candesartan cilexetil on striatin/nitric oxide pathway in regulating endothelial dysfunction in alcoholic liver disease
EASL LiverTree™, Balasubramaniyan Vairappan, 193378
Infections in Severe Alcoholic Hepatitis: Mayo Clinic Experience
EASL LiverTree™, Dame IDOSSA, 193379
Ethanol-Induced Oxidative Stress in Primary Human Hepatocytes is Suppressed by VTL C3A Cell-Secreted Factors.
EASL LiverTree™, Patricia Bedard, 196313
Discussion
EASL LiverTree™, Session Speakers, 198049
From microbiome to intestinal inflammation in ALD
EASL LiverTree™, Bernd Schnabl, 198048
Role of miRNAs in the sensitization of TLR4 signaling by ethanol
EASL LiverTree™, Laura E. Nagy, 198047
Defining meaningful clinical trial endpoints in patients with alcohol induced chronic liver disease: results from a multicentre feasibility trial
EASL LiverTree™, Louise China, 193375
No consensus among nutritional assessment tools for identification of malnutrition in patients with alcoholic liver disease
EASL LiverTree™, Chetan Kalal, 193376
Portal hemodynamics and systemic inflammation in patients with alcoholic hepatitis: a follow-up study
EASL LiverTree™, Laurent Spahr, 196311
THE UTILITY OF ALCOHOL SCREENING TESTS IN CLINICAL PRACTICE IN PATIENTS WITH END STAGE LIVER DISEASE AWAITING LIVER TRANSPLNATATION – EXPERIENCE OF A TERTIARY HEPATOLOGY CENTER
EASL LiverTree™, Corina Pietrareanu, 196312
Genetics of ALD: What do we learn from the risk loci about the disease?
EASL LiverTree™, Jochen Hampe, 198044
Burden and epidemiology of alcohol-related liver diseases in Europe and North America
EASL LiverTree™, David Leon, 198042
Welcome and opening remarks
EASL LiverTree™, Philippe MATHURIN, 198039
Welcome and opening remarks
EASL LiverTree™, Gyongyi Szabo, 198040
Universal screening of acute medical admissions for excess alcohol consumption: What’s the misuse?
EASL LiverTree™, Journal of Hepatology, 196043
Pre-natal and post-natal environment monitoring to prevent non-alcoholic fatty liver disease development
EASL LiverTree™, Journal of Hepatology, 196044
Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008–2013: A nationwide retrospective cohort study
EASL LiverTree™, Journal of Hepatology, 196045
HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs
EASL LiverTree™, Journal of Hepatology, 196046
Visualization of hepatitis E virus RNA and proteins in the human liver
EASL LiverTree™, Achim Weber, 196047
Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity
EASL LiverTree™, Journal of Hepatology, 196048
Intrahepatic CD206 macrophages contribute to inflammation in advanced viral-related liver disease
EASL LiverTree™, Charles-Antoine Dutertre, 196049
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study
EASL LiverTree™, Journal of Hepatology, 196050
Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter
EASL LiverTree™, Journal of Hepatology, 196059
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
EASL LiverTree™, Journal of Hepatology, 196060
Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
EASL LiverTree™, Journal of Hepatology, 196061
Biliary bile acids in hepatobiliary injury – What is the link?
EASL LiverTree™, Journal of Hepatology, 196062
Emerging molecular therapeutic targets for cholangiocarcinoma
EASL LiverTree™, Journal of Hepatology, 196063
Gallstone disease: Optimal timing of treatment
EASL LiverTree™, Journal of Hepatology, 196064
Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don’t seem to matter, unless you are an immigrant
EASL LiverTree™, Journal of Hepatology, 196065
Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection
EASL LiverTree™, Journal of Hepatology, 196066